Revvity (RVTY) is in focus after Argus published fresh research on October 23, 2026, alongside the recent launch of its AI-first Signals LabGistics platform for coordinating scientific workflows across drug discovery and manufacturing.
Revvity’s recent news arrives after a strong run, with the share price at US$158.77 and a 30 day share price return of 11.72%, building on a 90 day gain of 43.72% and a 1 year total shareholder return of 60.95%, even though the 5 year total shareholder return is down 9.16%.
Scan how Revvity’s AI push compares with other healthcare-focused AI opportunities by working through the hand picked list in the 34 healthcare AI stocks.
The recent surge in Revvity, backed by AI headlines and a higher Argus target, forces a simple question: Are investors finally paying up for the existing business, or mainly for a mood shift around the story?
Most Popular Narrative: 8% Overvalued
Revvity’s most followed valuation storyline pegs fair value at about $147.53, which sits below the latest close at $158.77 and points to a market that has already priced in a good chunk of the recovery thesis.
The current valuation suggests that investors are already paying a premium for sustained growth in areas such as Signals software, reproductive health, and ex-China immunodiagnostics, even though the company’s longer-term revenue and EPS trends have been under pressure.
See why 10 investors see Revvity as 8% overvalued.
Result: Fair Value of $147.53 (OVERVALUED)
Still, if Signals software delivers faster AI driven adoption or reproductive health and immunodiagnostics contracts scale more quickly, Revvity’s current “premium” story could appear conservative.
Find out about the key risks to this Revvity narrative.
Next Steps
Sentiment around Revvity is split, which is exactly why it pays to move quickly, inspect the data yourself, and decide where you stand. To weigh both the cautious flags and brighter spots in one place, start with the 1 key reward and 2 important warning signs.
Looking for more investment ideas beyond Revvity?
If Revvity has sharpened your thinking, use that momentum. The Simply Wall Street Screener helps you quickly filter for different types of opportunities that match your approach.
- Target reliable compounding potential by scanning companies that score well on balance sheet strength and fundamentals with the list of solid balance sheet and fundamentals (25 results).
- Hunt for potential mispricing by zeroing in on quality businesses that may be trading below their estimated worth using the 27 high quality undervalued stocks.
- Lock in income ideas by focusing on companies with yields above 5% through the 5 dividend fortresses.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com